Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP versus MP: Results from the VISTA trial
European Journal of Haematology,  Clinical Article

Delforge M et al. – The findings demonstrate clinically meaningful, transitory Health–related quality of life (HRQoL) decrements with bortezomib–melphalan–prednisone (VMP) and relatively lower HRQoL versus melphalan–prednisone (MP) during early treatment cycles, associated with the expected additional toxicities. However, HRQoL is not compromised in the long–term, recovering by the end–of–treatment visit to be comparable versus MP.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Physician Assistant

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Physician Assistant Articles

Indexed Journals in Physician Assistant: Advance for Physicians Assistants, American Family Physicianmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More